NEW YORK (360Dx) – Oxford Immunotec reported a 12 percent year-over-year increase in second quarter revenues today, driven by strong results from its tuberculosis business.

The company also launched the CE-marked T-Cell Select kit in Europe and select other countries today, which enables the complete automation of the firm's T-SPOT.TB test.

Total revenues for the quarter were $29.3 million, up from 26.1 million last year, and beating the analyst average estimate of $28.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.